Regsiter now for a personalized educational experience.
Already a member? Log In
By linking my Doximity account with UPMC Physician Resources, I acknowledge that:
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
UPMC has been selected as a center for the DREAM-HF-1 Study, a double-blind, randomized, sham-procedure-controlled, parallel-group efficacy and safety study of allogeneic mesenchymal precursor cells (rexlemestrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology.
We are currently enrolling men and women who have been diagnosed with heart failure with a reduced ejection fraction. The primary purpose of this study is to evaluate the effectiveness and safety of allogenic mesenchymal precursor cells (rexlemestrocel-L) versus a sham procedure to reduce recurrent non-fatal decompensated heart failure events.
The cells are human bone marrow derived from volunteer adult donors and are administered with intracardiac mapping during a single cardiac catheterization by our interventionalist.
Potential candidates for DREAM HF-1 must meet the following primary inclusion criteria:
For a full list of inclusion/exclusion criteria or to refer a patient:
Marc Simon, MD, is the principal investigator at UPMC. If you know a patient who may qualify, please call Kristin Shoemaker, RN, BSN, CCRC, research nurse coordinator at 412-692-2769 or email HeartFailureClinicalTrials@upmc.edu.